APOBEC3B

Across TCGA pan-cancer cohorts, APOBEC3B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated APOBEC3B data layer compared with 27 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher APOBEC3B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated APOBEC3B expression acts as an unfavorable survival marker.

SKCM, CESC, and SARC are the cancer types where APOBEC3B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	All	0.230	0.781	.004	15	view →
CESC	OS	Median	All	0.151	0.798	<.001	12	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

APOBEC3B–SKCM (OS)

Open the SKCM breakdown →